| __timestamp | BioMarin Pharmaceutical Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 129764000 | 205018000 |
| Thursday, January 1, 2015 | 152008000 | 392709000 |
| Friday, January 1, 2016 | 209620000 | 299694000 |
| Sunday, January 1, 2017 | 241786000 | 397061000 |
| Monday, January 1, 2018 | 315264000 | 434100000 |
| Tuesday, January 1, 2019 | 359466000 | 782200000 |
| Wednesday, January 1, 2020 | 524272000 | 1119900000 |
| Friday, January 1, 2021 | 470515000 | 2437500000 |
| Saturday, January 1, 2022 | 483669000 | 1560400000 |
| Sunday, January 1, 2023 | 577065000 | 1815800000 |
| Monday, January 1, 2024 | 1970500000 |
Unleashing insights
In the competitive world of biotechnology, cost efficiency is a critical factor for success. Over the past decade, Regeneron Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc. have showcased contrasting trends in their cost of revenue. From 2014 to 2023, Regeneron consistently outpaced BioMarin, with its cost of revenue peaking at approximately $1.82 billion in 2023, a staggering 780% increase from 2014. In contrast, BioMarin's cost of revenue grew by about 345% over the same period, reaching around $577 million in 2023.
This data highlights Regeneron's aggressive expansion and operational scale, while BioMarin's more modest growth reflects a different strategic approach. As these companies continue to innovate, understanding their cost structures provides valuable insights into their financial health and market strategies. Investors and industry analysts should keep a close eye on these trends to gauge future performance.
Cost Insights: Breaking Down Amgen Inc. and Regeneron Pharmaceuticals, Inc.'s Expenses
Cost of Revenue: Key Insights for Regeneron Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Limited
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Biogen Inc.'s Expenses
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs Alkermes plc
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs MorphoSys AG
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs Geron Corporation
Cost Insights: Breaking Down Viatris Inc. and BioMarin Pharmaceutical Inc.'s Expenses
BioMarin Pharmaceutical Inc. vs Jazz Pharmaceuticals plc: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Corcept Therapeutics Incorporated
Cost Insights: Breaking Down BioMarin Pharmaceutical Inc. and Veracyte, Inc.'s Expenses
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and HUTCHMED (China) Limited
Cost Insights: Breaking Down BioMarin Pharmaceutical Inc. and Evotec SE's Expenses